BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 380892)

  • 1. Inhibition of ovulation in women by intranasal treatment with a luteinizing hormone-releasing hormone agonist.
    Bergquist C; Nillius SJ; Wide L
    Contraception; 1979 May; 19(5):497-506. PubMed ID: 380892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue--a new approach to birth control?
    Nillius SJ; Bergquist C; Wide L
    Contraception; 1978 Jun; 17(6):537-45. PubMed ID: 352612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
    Lemay A; Faure N; Labrie F; Fazekas AT
    Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endometrial patterns in women on chronic luteinizing hormone-releasing hormone agonist treatment for contraception.
    Bergquist C; Nillius SJ; Wide L; Lindgren A
    Fertil Steril; 1981 Sep; 36(3):339-42. PubMed ID: 6793403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovulation inhibition with nafarelin acetate nasal administration for six months.
    Brenner PF; Shoupe D; Mishell DR
    Contraception; 1985 Dec; 32(6):531-51. PubMed ID: 2936564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns.
    Kuhl H; Jung C; Taubert HD
    Clin Endocrinol (Oxf); 1984 Aug; 21(2):179-88. PubMed ID: 6432376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic treatment with the gonadotropin-releasing hormone agonist D-Ser(TBU)6-EA10-LRH for contraception in women and men.
    Nillius SJ; Bergquist C; Wide L
    Int J Fertil; 1980; 25(3):239-46. PubMed ID: 6108935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a luteinizing hormone-releasing hormone agonist on luteal function in women.
    Bergquist C; Nillius SJ; Wide L
    Contraception; 1980 Sep; 22(3):287-93. PubMed ID: 7002443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovulation inhibition by daily i.m. administration of a highly active LH-RH analog (d-ser(TBU)6-LH-RH-(1-9)-nonapeptide-ethylamide).
    Baumann R; Kuhl H; Taubert HD; Sandow J
    Contraception; 1980 Feb; 21(2):191-7. PubMed ID: 6768492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of daily low dose mifepristone on the ovarian cycle and on dynamics of follicle growth.
    Cameron ST; Thong KJ; Baird DT
    Clin Endocrinol (Oxf); 1995 Oct; 43(4):407-14. PubMed ID: 7586613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue - a new approach to birth control?
    Nillius SJ; Bergquist C; Wide L
    Contraception; 1978 Jun; 17(6):537-44. PubMed ID: 363344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of ovulation by intranasal nafarelin, a new superactive agonist of GnRH.
    Gudmundsson JA; Nillius SJ; Bergquist C
    Contraception; 1984 Aug; 30(2):107-14. PubMed ID: 6238805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intranasal gonadotropin-releasing hormone agonist as a contraceptive agent.
    Bergquist C; Nillius SJ; Wide L
    Lancet; 1979 Aug; 2(8136):215-7. PubMed ID: 89330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a superactive luteinizing hormone-releasing factor agonist on gonadotropin and ovarian function during the menstrual cycle.
    Sheehan KL; Casper RF; Yen SS
    Am J Obstet Gynecol; 1979 Nov; 135(6):759-63. PubMed ID: 386801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Progress in the contraceptive use of the LH-RH agonist buserelin: intermittent medication with gestagen-induced withdrawal bleeding].
    Hardt W; Schmidt-Gollwitzer K; Nevinny-Stickel J; Schmidt-Gollwitzer M
    Geburtshilfe Frauenheilkd; 1982 Dec; 42(12):874-7. PubMed ID: 6819180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal LHRH agonist treatment for inhibition of ovulation in women: clinical aspects.
    Bergquist C; Nillius SJ; Wide L
    Clin Endocrinol (Oxf); 1982 Jul; 17(1):91-8. PubMed ID: 6811167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
    Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
    Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early follicular phase luteinizing hormone-releasing hormone agonist administration - effects on follicular maturation and corpus luteum function in women.
    Skarin G; Nillius SJ; Wide L
    Contraception; 1982 Jan; 25(1):31-9. PubMed ID: 6800690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic effects of the stimulatory luteinizing hormone-releasing hormone analogue D-Ser (TBU) 6-EA 10-LRH on the gonadotrophin and gonadal steroid secretion in women with amenorrhoea.
    Skarin G; Nillius SJ; Wide L
    Ups J Med Sci; 1980; 85(2):103-12. PubMed ID: 6787767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.